Ipsen Strengthens Early Clinical Pipeline With IRLAB’s Mesdepotem For Levodopa-Induced Dyskinesia
Upfront Of $28m
Ipsen has gained worldwide development and commercialization rights to IRLAB’s dopamine D3 antagonist, mesdepotem, in levodopa-induced dyskinesia in Parkinson’s disease.
